{"id":38429,"date":"2026-04-20T08:32:49","date_gmt":"2026-04-20T06:32:49","guid":{"rendered":"https:\/\/ggba.swiss\/?p=38429"},"modified":"2026-04-20T08:32:51","modified_gmt":"2026-04-20T06:32:51","slug":"onward-medical-raises-eur-40-million-to-extend-arc-therapy-commercialization","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/onward-medical-raises-eur-40-million-to-extend-arc-therapy-commercialization\/","title":{"rendered":"ONWARD Medical raises EUR 40 million to extend ARC therapy commercialization"},"content":{"rendered":"\n

ONWARD Medical<\/a> has raised EUR 40.6 million in gross proceeds through an accelerated bookbuild offering carried out as a private placement with institutional investors. The transaction includes a EUR 25 million investment from EQT Life Sciences and extends the company’s cash runway into the first quarter of 2028. The raise follows a EUR 50.85 million capital increase completed in 2025<\/a>, which was led by Ottobock and supported by Invus and the ASR Global Impact Equity Fund.<\/p>\n\n\n\n

ONWARD develops neurotechnology therapies designed to restore movement and autonomy in individuals living with spinal cord injuries and other movement impairments. Its ARC-EX System, a non-invasive platform cleared for commercial use in both the United States and Europe, is being rolled out across international markets. In parallel, the company is advancing its investigational ARC-IM implantable system, which targets unmet needs including blood pressure instability following spinal cord injury and is being explored in combination with brain-computer interface technologies and artificial intelligence to enable thought-driven movement.<\/p>\n\n\n\n

The new capital will fund product development, clinical studies, and regulatory work for ARC-IM, while supporting expanded commercial activities for ARC-EX across the US, Europe, and selected international markets. ONWARD is a Venture Kick, Venture Leaders, and Top 100 Swiss Startups alumnus, with a Science and Engineering Center in Lausanne where the foundational research behind ARC Therapy was developed at EPFL and CHUV.<\/p>\n\n\n\n

For a deeper look at the science behind ONWARD’s technology, listen to our Getting Serious podcast conversation with Gr\u00e9goire Courtine and Jocelyne Bloch<\/a>, the EPFL and CHUV researchers whose pioneering work on spinal cord stimulation laid the scientific foundation for ONWARD’s therapies, and who first demonstrated that a paralyzed man could walk again along the shores of Lake Geneva.<\/p>\n\n\n\n

\n